Sugi Predict

Sugi Predict / Targets / QRFPR

QRFPR

Pyroglutamylated RF-amide peptide receptor · Q96P65 · QRFPR on Sugi Atlas →

3,350 patent compounds predicted against QRFPR, 1,457 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7599390 SCHEMBL7599390 0.59 16/20
SCHEMBL566761 SCHEMBL566761 1.00 13/20
SCHEMBL116962 SCHEMBL116962 0.77 13/20
SCHEMBL175520 SCHEMBL175520 0.57 13/20
SCHEMBL117808 SCHEMBL117808 0.63 12/20
SCHEMBL117974 SCHEMBL117974 0.68 11/20
SCHEMBL565379 SCHEMBL565379 0.76 10/20
SCHEMBL169139 SCHEMBL169139 0.68 10/20
SCHEMBL116600 SCHEMBL116600 0.59 10/20
SCHEMBL118802 SCHEMBL118802 0.59 10/20
SCHEMBL119128 SCHEMBL119128 0.58 10/20
SCHEMBL118024 SCHEMBL118024 0.56 10/20
SCHEMBL118302 SCHEMBL118302 0.51 10/20
SCHEMBL3284914 SCHEMBL3284914 0.50 8/20
SCHEMBL7568588 SCHEMBL7568588 0.69 7/20
SCHEMBL7565608 SCHEMBL7565608 0.66 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7562296) 0.66 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7566303) 0.65 7/20
SCHEMBL7569688 SCHEMBL7569688 0.65 7/20
SCHEMBL7562339 SCHEMBL7562339 0.64 7/20

Clinical trials — most relevant to QRFPR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis PHASE4COMPLETED
Saxenda: Underlying Mechanisms and Clinical Outcomes PHASE4ACTIVE_NOT_RECRUITING
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET PHASE2/PHASE3COMPLETED
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET PHASE2/PHASE3COMPLETED
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion PHASE3COMPLETED
A Research Study of VCT220 in Adult Chinese Participants With Obesity PHASE3ACTIVE_NOT_RECRUITING
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment PHASE1/PHASE2RECRUITING
68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks PHASE2COMPLETED
Effects of Exenatide on Hypothalamic Obesity PHASE1/PHASE2COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids. PHASE2COMPLETED
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease PHASE2COMPLETED
Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans PHASE1COMPLETED
A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects PHASE1COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides PHASE1COMPLETED
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention nanNOT_YET_RECRUITING
The Effect of Weekly Semaglutide Treatment on Energy Expenditure nanCOMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
A Study on the Effects of Combined FMT on Gut Microbiota and Eating Disorder Symptoms in AN nanNOT_YET_RECRUITING
Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients nanCOMPLETED
Selective Activation of the Adrenomedullin Receptors in Migraine nanNOT_YET_RECRUITING
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD nanRECRUITING
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy nanCOMPLETED
Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide nanUNKNOWN
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33) nanCOMPLETED
Auricular Vagus Stimulation in Obesity nanACTIVE_NOT_RECRUITING
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms nanCOMPLETED
Measurement of Relaxin Peptide in Multiple Sclerosis (MS) nanCOMPLETED
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a QRFPR binder may also engage these)

ProteinNameSimilarity
P83858 — 0.995 P83858 →
P83861 — 0.993 P83861 →
Q5DUB3 — 0.951 Q5DUB3 →
TACR1 Substance-P receptor 0.949 landscape →
Q5DUB1 — 0.943 Q5DUB1 →
P14600 — 0.940 P14600 →
P30548 — 0.939 P30548 →
P30547 — 0.939 P30547 →
GALR1 Galanin receptor type 1 0.930 landscape →
NMBR Neuromedin-B receptor 0.930 landscape →
O18914 — 0.929 O18914 →
P24053 — 0.929 P24053 →
Q62805 — 0.928 Q62805 →
CRHR2 Corticotropin-releasing factor receptor 2 0.927 landscape →
O54799 — 0.925 O54799 →
B2ZI34 — 0.924 B2ZI34 →
P47866 — 0.923 P47866 →
O42602 — 0.923 O42602 →
EDNRB Endothelin receptor type B 0.923 landscape →
P56497 — 0.922 P56497 →
P04000 — 0.922 P04000 →
P04001 — 0.920 P04001 →
P56479 — 0.920 P56479 →
P87367 — 0.920 P87367 →
Q60748 — 0.919 Q60748 →
Q90328 — 0.918 Q90328 →
Q9BGI7 — 0.918 Q9BGI7 →
O18913 — 0.918 O18913 →
Q95170 — 0.918 Q95170 →
Q9N0W7 — 0.917 Q9N0W7 →